ScinoPharm Taiwan Ltd
TWSE:1789

Watchlist Manager
ScinoPharm Taiwan Ltd Logo
ScinoPharm Taiwan Ltd
TWSE:1789
Watchlist
Price: 22.7 TWD -1.09% Market Closed
Market Cap: 17.9B TWD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ScinoPharm Taiwan Ltd stock under the Base Case scenario is 20.39 TWD. Compared to the current market price of 22.7 TWD, ScinoPharm Taiwan Ltd is Overvalued by 10%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
20.39 TWD
Overvaluation 10%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

5.1
P/S
P/S
Price to Sales
5.1
vs History
98
vs Industry
22
Median 3Y
6.5
Median 5Y
6.6
Industry
2.4
Forward
5.8
More Details
44.9
P/E
P/E
Price to Earnings
44.9
vs History
98
vs Industry
7
Median 3Y
64.7
Median 5Y
70.6
Industry
20.5
Forward
67.4
More Details
29.7
P/OCF
P/OCF
Price to OCF
29.7
vs History
47
vs Industry
8
Median 3Y
33.7
Median 5Y
30.2
Industry
15.4
More Details
72.4
P/FCFE
P/FCFE
Price to FCFE
72.4
vs History
31
vs Industry
1
Median 3Y
71.8
Median 5Y
55.2
Industry
22.6
More Details
1.7
P/B
P/B
Price to Book Value
1.7
vs History
85
vs Industry
39
Median 3Y
1.9
Median 5Y
1.9
Industry
2
More Details
4.1
EV/S
EV/S
Enterprise Value to Sales
4.1
vs History
98
vs Industry
24
Median 3Y
5.3
Median 5Y
5.4
Industry
2.5
Forward
4.6
More Details
10.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
10.4
vs History
98
vs Industry
14
Median 3Y
13.3
Median 5Y
13.4
Industry
4.9
More Details
15.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
15.7
vs History
98
vs Industry
19
Median 3Y
21.4
Median 5Y
22
Industry
12.6
Forward
594.7
More Details
32.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
32.2
vs History
98
vs Industry
9
Median 3Y
45.9
Median 5Y
46.6
Industry
15.6
Forward
50.2
More Details
23.8
EV/OCF
EV/OCF
Enterprise Value to OCF
23.8
vs History
49
vs Industry
10
Median 3Y
27.2
Median 5Y
24.7
Industry
13.9
More Details
42.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
42.3
vs History
28
vs Industry
3
Median 3Y
42.9
Median 5Y
36
Industry
17.7
More Details
1.9
EV/IC
EV/IC
Enterprise Value to IC
1.9
vs History
90
vs Industry
34
Median 3Y
2.2
Median 5Y
2.2
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
ScinoPharm Taiwan Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
TW
ScinoPharm Taiwan Ltd
TWSE:1789
17.9B TWD 5.1 44.9 15.7 32.2
US
Eli Lilly and Co
NYSE:LLY
793.6B USD 17.6 74.9 43.5 48
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
393.8B USD 4.4 28 13.1 17.2
DK
Novo Nordisk A/S
CSE:NOVO B
2.3T DKK 8.1 23.3 15.3 17.4
CH
Roche Holding AG
SIX:ROG
246.5B CHF 4.2 21.4 11.9 14.2
US
Merck & Co Inc
NYSE:MRK
235.8B USD 3.7 13.8 9.3 10.9
UK
AstraZeneca PLC
LSE:AZN
180B GBP 4.3 33.1 127.1 194.1
CH
Novartis AG
SIX:NOVN
202B CHF 4.4 19.1 11.6 14.8
IE
Endo International PLC
LSE:0Y5F
166.1B USD 71.6 -56.8 265.3 665.3
US
Pfizer Inc
NYSE:PFE
148.9B USD 2.3 18.5 8.8 12.5
P/E Multiple
Earnings Growth PEG
TW
ScinoPharm Taiwan Ltd
TWSE:1789
Average P/E: 30.8
44.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
74.9
48%
1.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
28
26%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
23.3
19%
1.2
CH
Roche Holding AG
SIX:ROG
21.4
16%
1.3
US
Merck & Co Inc
NYSE:MRK
13.8
17%
0.8
UK
AstraZeneca PLC
LSE:AZN
33.1
36%
0.9
CH
Novartis AG
SIX:NOVN
19.1
16%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56.8 N/A N/A
US
Pfizer Inc
NYSE:PFE
18.5
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
TW
ScinoPharm Taiwan Ltd
TWSE:1789
Average EV/EBITDA: 397.1
15.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
43.5
30%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.1
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
15.3
15%
1
CH
Roche Holding AG
SIX:ROG
11.9
8%
1.5
US
Merck & Co Inc
NYSE:MRK
9.3
9%
1
UK
AstraZeneca PLC
LSE:AZN
127.1
9%
14.1
CH
Novartis AG
SIX:NOVN
11.6
5%
2.3
IE
E
Endo International PLC
LSE:0Y5F
265.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.8
3%
2.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
TW
ScinoPharm Taiwan Ltd
TWSE:1789
Average EV/EBIT: 1 702.6
32.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48
33%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17.2
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
17.4
16%
1.1
CH
Roche Holding AG
SIX:ROG
14.2
9%
1.6
US
Merck & Co Inc
NYSE:MRK
10.9
12%
0.9
UK
AstraZeneca PLC
LSE:AZN
194.1
21%
9.2
CH
Novartis AG
SIX:NOVN
14.8
8%
1.9
IE
E
Endo International PLC
LSE:0Y5F
665.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
12.5
10%
1.3

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 240,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.